Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT trial of ctDNA-guided adjuvant chemotherapy after surgery for high-risk rectal cancer
NL-OMON60515Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in rectal cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Disease-free survival. Started Dec 2025; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON60515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60515.